Organization
Gustave Roussy, Villejuif, France
9 abstracts
3 posters
Abstract
Tumor fraction to improve patient selection for oncology early phase clinical trials: Analysis of two precision medicine studies.Org: Early Phase Clinical Trials Unit and Thoracic Unit, Institut Bergonié, Bordeaux, France, Bergonie Institute, Inserm CIC1401, Bordeaux, France, Institut Bergonié, Molecular Biology Department, Bordeaux, France, Molecular Pathology Unit-Department of Biopathology, Institut Bergonié, Bordeaux, France, Institut Bergonie, Molecular Biology Department, Bordeaux, France,
Abstract
Chemotherapy and liver transplantation versus chemotherapy alone in patients with definitively unresectable colorectal liver metastases: A prospective multicentric randomized trial (TRANSMET).Org: Assistance Publique - Hôpitaux de Paris (APHP), University Paris-Saclay, Clinical Research Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy, Service de Chirurgie HPB Transplantation, Hopital Haut Leveque,
Abstract
A retrospective comparison of abbreviated course “7+7” vs standard hypomethylating agent plus venetoclax doublets in older/unfit patients with newly diagnosed acute myeloid leukemia.Org: The University of Texas MD Anderson Cancer Center, Department of Leukemia, Centre Hospitalier Régional Universitaire de Nîmes, Hopital Cochin, Groupement des Hôpitaux de l'Institut Catholique de Lille,
Abstract
EGRET: A first-in-human study of the novel antibody-drug conjugate (ADC) AZD9592 as monotherapy or combined with other anticancer agents in patients (pts) with advanced solid tumors.Org: Perelman Center for Advanced Medicine, Philadelphia, PA, Lifespan Cancer Institute, Providence, RI, Virginia Cancer Specialists, Fairfax, VA, Peter MacCallum Cancer Centre, Melbourne, Australia, MD Anderson Cancer Center, Houston, TX,
Abstract
LESS: Single-arm study to de-escalate adjuvant endocrine therapy duration in post-menopausal women with HR+ HER2- early-stage breast cancer at very low risk of metastasis.Org: Centre Hospitalier Universitaire, Limoges, France, Office of Biostatistics and Epidemiology, Gustave Roussy, Villejuif, France, Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France, Centre Eugène Marquis, Rennes, France, Centre Antoine Lacassagne, Nice, France,
Abstract
Overall survival and long-term safety in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Updated analyses from INTRIGUE.Org: Sarcoma Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, United Kingdom, Centre Léon Bérard, Lyon, France, Dana-Farber Cancer Institute, Boston, MA, USA, Leiden University Medical Center, Leiden, Netherlands, University Hospitals Leuven, Department of General Medical Oncology, Leuven Cancer Institute, KU Leuven, Leuven, Belgium,
Abstract
Outcomes in patients with advanced gastrointestinal stromal tumor who did not have baseline ctDNA detected in the INTRIGUE study.Org: Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL, Sarcoma Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, United Kingdom, Dana-Farber Cancer Institute, Boston, MA, USA, Leiden University Medical Center, Leiden, Netherlands, University Hospitals Leuven, Department of General Medical Oncology, Leuven Cancer Institute, KU Leuven, Leuven, Belgium,
Abstract
Encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for unresectable locally advanced or metastatic BRAF V600-mutant melanoma: Results from STARBOARD safety lead-in (SLI).Org: University Hospital Essen, Essen, Germany, University Hospital Zurich, Zurich, Switzerland, Gustave Roussy, Villejuif, France, Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA, Massachusetts General Hospital, Boston, MA, USA,
Abstract
KEYVIBE-010: Adjuvant coformulated vibostolimab with pembrolizumab versus adjuvant pembrolizumab in patients with high-risk stage II-IV melanoma.Org: Faculty of Medicine University Medical Center and Princess Máxima Center, Utrecht, the Netherlands, Comprehensive Cancer Center Munich and Technical University Munich & Ludwig Maximilian University, Munich, Netherlands, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, University Hospital Essen, University Duisburg-Essen, West German Cancer Centre (WTZ), and German Cancer Consortium, Partner Site Essen, Essen, Germany, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy,